The association between body mass index and efficacy of pembrolizumab as second‐line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma by Xinyi Zhang, Mengyu Rui, Chao Lin, Zhi Li, Dongliang Wei, Ruxue Han, Houyu Ju, Guoxin Ren

Get full text

The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a single center, real world study in China by Zongyu Fan, Zongyu Fan, Zongyu Fan, Rongrong Hui, Rongrong Hui, Houyu Ju, Houyu Ju, Houyu Ju, Yunteng Wu, Yunteng Wu, Yunteng Wu, Xuhui Ma, Xuhui Ma, Xuhui Ma, Hao Song, Hao Song, Hao Song, Yang Liu, Yang Liu, Yang Liu, Mengyu Rui, Mengyu Rui, Mengyu Rui, Xinrong Geng, Xinrong Geng, Xinrong Geng, Minqi Zhao, Minqi Zhao, Yingye Xin, Yingye Xin, Dongliang Wei, Dongliang Wei, Dongliang Wei, Guoxin Ren, Guoxin Ren, Guoxin Ren

Get full text

The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification by Chaoji Shi, Houyu Ju, Rong Zhou, Shengming Xu, Yunteng Wu, Ziyue Gu, Ying Wang, Wanling Chen, Xinyi Huang, Yong Han, Shuyang Sun, Chuwen Li, Min Wang, Guoyu Zhou, Zhiyuan Zhang, Jiang Li, Guoxin Ren

Get full text